Researchers at the IDM, the Principe Felipe Research Center (CIPF), CIBER-BBN and the Institute for Research in Biomedicine (IRB) of Barcelona have inhibited tumor growth and reduced metastasis, as well as the toxicity of the antitumor drug Navitoclax in preclinical animal models of triple negative breast cancer (TNBC).
This type of TNBC tumor does not express any of the receptors involved in most breast cancers (estrogen, progesterone and HER2), so the most common treatments, such as the hormone therapy, are not viable in these patients.
The study proves that a combined treatment of a senescence inducer and a senolytic nanoparticle selectively removes senescent cells, delays tumor growth and reduces metastasis in a model of aggressive breast cancer.
The results are published in the Journal of Controlled Release (JCR)
